Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan. more
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | 589.00K | 39.85M | 19.05M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":1.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.8,"profit":true}] | |
Cost of Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Profit | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 9.47M | 23.29M | 21.62M | 29.61M | [{"date":"2020-12-31","value":31.97,"profit":true},{"date":"2021-12-31","value":78.66,"profit":true},{"date":"2022-12-31","value":73.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (9.47M) | (22.70M) | 18.23M | (10.56M) | [{"date":"2020-12-31","value":-51.94,"profit":false},{"date":"2021-12-31","value":-124.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-57.96,"profit":false}] | |
Total Non-Operating Income/Expense | (15.15M) | (33.99M) | (23.00K) | 589.00K | [{"date":"2020-12-31","value":-2572.84,"profit":false},{"date":"2021-12-31","value":-5770.46,"profit":false},{"date":"2022-12-31","value":-3.9,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |
Pre-Tax Income | (24.62M) | (56.69M) | 18.20M | (9.97M) | [{"date":"2020-12-31","value":-135.25,"profit":false},{"date":"2021-12-31","value":-311.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-54.79,"profit":false}] | |
Income Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | (24.62M) | (56.69M) | 17.89M | (9.99M) | [{"date":"2020-12-31","value":-137.63,"profit":false},{"date":"2021-12-31","value":-316.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-55.83,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (24.62M) | (56.69M) | 17.89M | (9.99M) | [{"date":"2020-12-31","value":-137.63,"profit":false},{"date":"2021-12-31","value":-316.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-55.83,"profit":false}] | |
EPS (Diluted) | - | (9.11) | 0.76 | (0.47) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1202.05,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-62.51,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
IRD | |
---|---|
Current Ratio | 10.68 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IRD | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IRD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IRD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
EV/R | 0.00 |
EV/Ebitda | NM |
Opus Genetics, Inc. (IRD) share price today is $0.9871
Yes, Indians can buy shares of Opus Genetics, Inc. (IRD) on Vested. To buy Opus Genetics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IRD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Opus Genetics, Inc. (IRD) via the Vested app. You can start investing in Opus Genetics, Inc. (IRD) with a minimum investment of $1.
You can invest in shares of Opus Genetics, Inc. (IRD) via Vested in three simple steps:
The 52-week high price of Opus Genetics, Inc. (IRD) is $3.4. The 52-week low price of Opus Genetics, Inc. (IRD) is $0.81.
The price-to-earnings (P/E) ratio of Opus Genetics, Inc. (IRD) is
The price-to-book (P/B) ratio of Opus Genetics, Inc. (IRD) is 0.00
The dividend yield of Opus Genetics, Inc. (IRD) is 0.00%
The market capitalization of Opus Genetics, Inc. (IRD) is
The stock symbol (or ticker) of Opus Genetics, Inc. is IRD